Skip to main content

Petrus Resources Declares Monthly Dividend for March 2026

CALGARY, Alberta, March 03, 2026 (GLOBE NEWSWIRE) — Petrus Resources Ltd. (“Petrus” or the “Company”) (TSX: PRQ) is pleased to confirm that its Board of Directors has declared a monthly dividend in the amount of $0.01 per share payable March 31, 2026, to shareholders of record on March 17, 2026. The dividend is designated as an eligible dividend for Canadian income tax purposes. Dividend Reinvestment Plan (“DRIP”)Petrus’ DRIP enables eligible shareholders to reinvest all or part of their cash dividends into additional common shares of the Company. Participation in the DRIP is optional. Eligible shareholders who elect to reinvest their cash dividends under the DRIP will receive common shares issued from treasury at a discount of 3% from the market price of the common shares. To participate in the DRIP, registered...

Continue reading

Sprott Focus Trust, Inc. (Nasdaq-FUND) Declares First Quarter Common Stock Distribution of $0.1335 Per Share

TORONTO, March 03, 2026 (GLOBE NEWSWIRE) — Sprott Focus Trust, Inc. (Nasdaq-FUND) (the “Fund” or “FUND”) has declared a quarterly distribution of $0.1335 per share on its Common Stock. The distribution, optionally payable in additional shares of Common Stock or in cash by specific stockholder election, is to be paid on March 27, 2026 to stockholders of record at the close of business on March 13, 2026 (ex-dividend on March 13, 2026). The price of shares issued for reinvestment will be determined on March 20, 2026. The Fund currently has adopted a Distribution Policy of paying quarterly distributions on its Common Stock. Distributions are being made at the annual rate of 6% of the rolling average of the prior four calendar quarter-end net asset values (“NAVs”), with the fourth quarter distribution being the greater of 1.50% of the...

Continue reading

InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement

NEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) — InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) today announced that on February 25, 2026 the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(2), as the Company’s closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until August 24, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Ordinary Shares must meet or exceed $1.00 per share for at least 10 consecutive business...

Continue reading

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345  Date   Total number of shares Total number of voting rights02/28/2026   278,352,082     Total gross of voting rights: 278,352,082    Total net* of voting rights: 278,236,200  * Net total = total number of voting rights attached to shares – shares without voting rightsAttachmentPDF Version

Continue reading

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will present at the Citizens Life Sciences Conference on Wednesday, March 11, 2026 at 3:25pm ET. A live webcast and recording of this presentation will be available from the “Investors & Media” section of ProQR’s website (www.proqr.com) under “Events”. Archived webcasts will be available for approximately 30 days following the presentation date. About Axiomer™ ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of...

Continue reading

Kraken Robotics Announces Signing of Strategic Acquisition to Expand Global Maritime Capabilities

$615 Million Acquisition of the Covelya Group Will Be Partially Financed Through a $350 Million Public Offering of Subscription Receipts Preliminary 2025 Year-End Results and Stand-Alone 2026 Guidance Provided for Kraken Robotics THIS RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES THE BASE SHELF PROSPECTUS IS ACCESSIBLE, AND THE SHELF PROSPECTUS SUPPLEMENT FOR THE PUBLIC OFFERING AND ANY AMENDMENT TO THE DOCUMENTS WILL BE ACCESSIBLE, WITHIN TWO BUSINESS DAYS, THROUGH SEDAR+ (All dollar amounts are expressed in Canadian dollars, unless otherwise noted.) ST. JOHN’S, Newfoundland, March 03, 2026 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (“Kraken” or the “Company”) (TSX-V: PNG), is pleased to announce that it has entered into an agreement to acquire Covelya Group Limited (“Covelya...

Continue reading

Dave Announces Proposed Offering of Convertible Notes

Company plans to enter into capped call transactions and repurchase shares of its common stock to opportunistically create value for shareholders Los Angeles, March 03, 2026 (GLOBE NEWSWIRE) — Dave Announces Proposed Offering of Convertible Notes Company plans to enter into capped call transactions and repurchase shares of its common stock to opportunistically create value for shareholders LOS ANGELES, CA – March 3, 2026 – Dave Inc. (NASDAQ: DAVE) (“Dave” or the “Company”) today announced that it plans to offer, subject to market and other conditions, $150 million principal amount of its Convertible Senior Notes due 2031 (the “notes”) through a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Dave expects...

Continue reading

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-April Phase 1b enrollment ongoing in celiac disease and trial cohort initiated in eosinophilic esophagitis for ANB033, a CD122 antagonist GSK announced strong commercial performance for Jemperli, growing >13% quarter-over-quarter to $343 million in Q4 2025, implying a ~$1.4 billion annualized run rate Expect to achieve >$390 million in annualized Jemperli royalties payable to Anaptys at GSK’s peak sales guidance of >$2.7 billion as early as 2029 Year-end 2025 cash and investments of ~$311 millionSAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today provided...

Continue reading

Fuel Tech Reports 2025 Fourth Quarter and Full Year Financial Results

WARRENVILLE, Ill., March 03, 2026 (GLOBE NEWSWIRE) — Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water treatment technologies in utility and industrial applications, today reported financial results for the fourth quarter and full year ended December 31, 2025. “2025 was a year of achievement for Fuel Tech, highlighted by a resurgence at our FUEL CHEM® operations that produced the highest annual segment revenue since 2018, a broadened opportunity landscape at our Air Pollution Control (“APC”) business segment driven in large part by the expected growth of power generation to support data center construction and operation, and measurable progress at our Dissolved Gas Infusion (“DGI”) business segment,” said Vincent J. Arnone, President and CEO....

Continue reading

Latham Group Acquires Freedom Pools

Combination Creates a Market-Leader in Fiberglass Pools Across Australia and New Zealand Transaction Expected to be Immediately Accretive to EarningsLATHAM, N.Y., March 03, 2026 (GLOBE NEWSWIRE) — Latham Group, Inc. (Nasdaq: SWIM), the largest designer, manufacturer, and marketer of in-ground residential swimming pools in North America, Australia, and New Zealand, today announced that it has acquired Freedom Pools, a fiberglass pool manufacturer and installer operating in Australia and New Zealand. The transaction was completed on February 26, 2026. The acquisition is expected to be immediately accretive to Latham’s earnings, adding approximately $20 million in net sales and approximately $4 million in adjusted EBITDA, on an annualized basis, before acquisition synergies. The purchase price was approximately $17 million, and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.